Considering only EFV-containing regimens, adolescents on d4T + 3TC
+ EFV and TDF + FTC + EFV were more likely to report multiple symptoms than those on ABC + 3TC
+ EFV (aOR 3.
sup] Although both TDF and 3TC
can be used to treat both HBV and HIV, studies on the effect of TDF and 3TC
on naive patients with HBV and HIV co-infections are rare.
The instrument was set at 300, 285 and 270 nm for NVP, 3TC
and d4T respectively.
It has been shown that removal of 3TC
from a failing antiviral regimen leads to an average increase of 0.
When Reverset was used without other cytidine analogs, 3TC
and FTC, it was a very powerful drug against resistant virus.
In a retrospective analysis of the subgroup of patients with high viral load at baseline (greater than 100,000 copies/mL), the combination of Sustiva, AZT and 3TC
also provided suppression of viral load through 48 weeks.
Until the studies began, the combination of AZT and 3TC
offered the best chance of extending life, but these two drugs offered little chance of reducing the virus to undetectable levels.
FTC and 3TC
are structurally very similar, FTC having just one additional fluorine molecule.
The aim of the present study was to examine the influence of immunological status, sex, BMI and dose of d4T on the steady state pharmacokinetics of 3TC
and d4T in HIV-infected patients on treatment with FDCs in India.
ZDV + ABC (n=6) TAMs or wild type No M184V or other ABC mutations ZDV + 3TC
(n=4) M184V [right arrow] TAMs ABC + 3TC
(n=6) M184V [right arrow] K65R and/or L74V Table 2: Factors that influence the decision to change a failing antiretroviral regimen in children.
The 8 months after November 1995, however, witnessed approval by the US Food & Drug Administration (FDA) of 5 new anti-HIV drugs--the nucleoside analog 3TC
, 3 new PIs--saquinavir (Invirase), ritonavir (Norvir), and indinavir (Crixivan)--and the non-nucleoside reverse transcriptase inhibitor (NNRTI) nevirapine (Viramune).
Avexa research indicates that there is a need for new drugs that will treat the resistant virus emerging during 3TC
therapy (a first line anti-HIV treatment) and SPD754 will be developed to target this market.
Hepatic failure was reported in six patients on NVP, seven on ZDV, five on 3TC
, and five on d4T.
Susceptibility to 3TC
decreased in 19 patients, susceptibility to ddI decreased in 6 patients, and susceptibility to a nucleoside not used in this regimen--abacavir (ABC)--decreased in 3 patients.